Mice with a dysfunctional myxovirus resistance-1 (dMx1) gene transport intranasally-instilled PR8 influenza virus to the olfactory bulb (OB) within 4 h post-infection. To determine if the presence of a functional Mx1 (fMx1) gene would influence this brain viral localization and/or disease, we infected mature C57BL/6 dMx1 and fMx1 mice under the same conditions and observed sickness behaviors, viral nucleoprotein (NP) RNA expression and innate immune mediator (IIM) mRNA expression in selected tissues at 15 and 96 h post-infection. Virus invaded the OB and lungs comparably in both sub-strains at 15 and 96 h as determined by nested PCR. In contrast, virus was present in blood and somatosensory cortex of dMx1, but not fMx1 mice at 96 h. At 15 h, sickness behaviors were comparable in both sub-strains. By 96 h dMx1, but not fMx1, were moribund. In both 15 and 96 h lungs, viral NP was significantly elevated in the dMx1 mice compared to the fMx1 mice, as determined by quantitative PCR. OB expression of most IIM mRNAs was similar at both time periods in both sub-strains. In contrast, lung IIM mRNAs were elevated in fMx1 at 15 h, but by 96 h were consistently reduced compared to dMx1 mice. In conclusion, functional Mx1 did not alter OB invasion by virus but attenuated illness compared to dMx1 mice. Inflammation was similar in OBs and lungs of both strains at 15 h but by 96 h it was suppressed in lungs, but not in OBs, of fMx1 mice.
Introduction
Influenza virus is an important pathogen of humans and many mammalian and avian species. While human strains are not generally thought to invade the brain, growing evidence suggests that neurological complications of influenza (distinct from Reye's syndrome) are not rare in children (Newland et al., 2007; Studahl, 2003; Sugaya, 2002; Wang et al., 2010; Webster et al., 2010) . Neurological complications have also been reported in adults infected with pandemic strains to which the victims had no pre-existing immunity (Fugate et al., 2010; Kristensson, 2006; Majde et al., 2007) . Despite these reports, the relationship of human influenza viruses and the brain during severe infections has received little attention.
The innate immune system is the first line of defense against all infectious agents (Germain, 2004; Kumagai et al., 2008) . This system employs numerous innate immune mediators (IIMs), including eicosenoids, lectins, cytokines, chemokines, defensins, and anti-viral enzymes, to impair viral replication. Selected cytokines activate pathophysiological changes, often termed the acute phase response, 'flu' syndrome, or sickness behavior.
Sickness behaviors are manifestations of pathophysiological changes in the brain that accompany overt viral infections and include changes in body temperature and sleep, headache, anorexia, and cognitive impairment (Majde and Krueger, 2005; Nicholson, 1998) . Severe influenza in mice is characterized by a precipitous reduction in body temperature (Wong et al., 1997) together with a disappearance of circadian temperature rhythms (Conn et al., 1995; Majde et al., 2007) . In addition, infected mice demonstrate reduced locomotor activity that is also accompanied by a loss of circadian rhythms (Conn et al., 1995) . These mice also lose up to 20% of their body weight as a consequence of reduced water and food intake (Conn et al., 1995) . The time of onset and severity of these responses to mouse-adapted influenza virus in a particular mouse strain is determined by the dose of virus administered (Conn et al., 1995) .
Key cytokines produced in response to viral challenge are the well-characterized proinflammatory cytokines interleukin-1 beta (IL1b) and tumor necrosis factor alpha (TNFa) as well as antiinflammatory type I interferons (IFNs) (Amadori, 2007) . Influenza virus induces these cytokines through at least two Toll-like receptors (TLRs): intracellular TLR7, which binds to single-stranded viral RNA released into the cytosol, and TLR3, which responds to both extracellular and intracellular double-stranded (ds) RNA made during viral replication (Majde et al., 2010) .
The type I IFNs include several isoforms of IFNa and one isoform of IFNb that are widely recognized for their antiviral activity. These
